284 related articles for article (PubMed ID: 35074907)
1. Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model.
Kumar S; Schoonderwoerd MJA; Kroonen JS; de Graaf IJ; Sluijter M; Ruano D; González-Prieto R; Verlaan-de Vries M; Rip J; Arens R; de Miranda NFCC; Hawinkels LJAC; van Hall T; Vertegaal ACO
Gut; 2022 Nov; 71(11):2266-2283. PubMed ID: 35074907
[TBL] [Abstract][Full Text] [Related]
2. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
3. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype.
Biederstädt A; Hassan Z; Schneeweis C; Schick M; Schneider L; Muckenhuber A; Hong Y; Siegers G; Nilsson L; Wirth M; Dantes Z; Steiger K; Schunck K; Langston S; Lenhof HP; Coluccio A; Orben F; Slawska J; Scherger A; Saur D; Müller S; Rad R; Weichert W; Nilsson J; Reichert M; Schneider G; Keller U
Gut; 2020 Aug; 69(8):1472-1482. PubMed ID: 32001555
[TBL] [Abstract][Full Text] [Related]
4. A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models.
Lightcap ES; Yu P; Grossman S; Song K; Khattar M; Xega K; He X; Gavin JM; Imaichi H; Garnsey JJ; Koenig E; Zhang H; Lu Z; Shah P; Fu Y; Milhollen MA; Hatton BA; Riceberg J; Shinde V; Li C; Minissale J; Yang X; England D; Klinghoffer RA; Langston S; Galvin K; Shapiro G; Pulukuri SM; Fuchs SY; Huszar D
Sci Transl Med; 2021 Sep; 13(611):eaba7791. PubMed ID: 34524860
[TBL] [Abstract][Full Text] [Related]
5. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
6. T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia.
Lam V; Roleder C; Liu T; Bruss N; Best S; Wang X; Phillips T; Shouse G; Berger AJ; Alinari L; Wang L; Siddiqi T; Pennock ND; Danilov AV
Mol Cancer Ther; 2023 Sep; 22(9):1040-1051. PubMed ID: 37420267
[TBL] [Abstract][Full Text] [Related]
7. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma.
Liu X; Tang R; Xu J; Tan Z; Liang C; Meng Q; Lei Y; Hua J; Zhang Y; Liu J; Zhang B; Wang W; Yu X; Shi S
Gut; 2023 Nov; 72(12):2329-2343. PubMed ID: 37541772
[TBL] [Abstract][Full Text] [Related]
8. SUMO Modification of PAF1/PD2 Enables PML Interaction and Promotes Radiation Resistance in Pancreatic Ductal Adenocarcinoma.
Rauth S; Karmakar S; Shah A; Seshacharyulu P; Nimmakayala RK; Ganguly K; Bhatia R; Muniyan S; Kumar S; Dutta S; Lin C; Datta K; Batra SK; Ponnusamy MP
Mol Cell Biol; 2021 Nov; 41(12):e0013521. PubMed ID: 34570619
[TBL] [Abstract][Full Text] [Related]
9. Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer.
Boelaars K; Goossens-Kruijssen L; Wang D; de Winde CM; Rodriguez E; Lindijer D; Springer B; van der Haar Àvila I; de Haas A; Wehry L; Boon L; Mebius RE; van Montfoort N; Wuhrer M; den Haan JMM; van Vliet SJ; van Kooyk Y
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37940346
[TBL] [Abstract][Full Text] [Related]
10. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry.
Brouwer TP; de Vries NL; Abdelaal T; Krog RT; Li Z; Ruano D; Fariña A; Lelieveldt BPF; Morreau H; Bonsing BA; Vahrmeijer AL; Koning F; de Miranda NFCC
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793870
[TBL] [Abstract][Full Text] [Related]
11. Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by activating Stat1-CCL2-mediated immunity.
Bhoopathi P; Kumar A; Pradhan AK; Maji S; Mannangatti P; Windle JJ; Subler MA; Zhang D; Vudatha V; Trevino JG; Madan E; Atfi A; Sarkar D; Gogna R; Das SK; Emdad L; Fisher PB
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935566
[TBL] [Abstract][Full Text] [Related]
12. The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation.
Nakamura A; Grossman S; Song K; Xega K; Zhang Y; Cvet D; Berger A; Shapiro G; Huszar D
Blood; 2022 May; 139(18):2770-2781. PubMed ID: 35226739
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic Stellate Cells Promote Tumor Progression by Promoting an Immunosuppressive Microenvironment in Murine Models of Pancreatic Cancer.
Li C; Cui L; Yang L; Wang B; Zhuo Y; Zhang L; Wang X; Zhang Q; Zhang S
Pancreas; 2020 Jan; 49(1):120-127. PubMed ID: 31856087
[TBL] [Abstract][Full Text] [Related]
14. The SUMO pathway in pancreatic cancer: insights and inhibition.
Schneeweis C; Hassan Z; Schick M; Keller U; Schneider G
Br J Cancer; 2021 Feb; 124(3):531-538. PubMed ID: 33071285
[TBL] [Abstract][Full Text] [Related]
15. CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer.
Faraoni EY; Singh K; Chandra V; Le Roux O; Dai Y; Sahin I; O'Brien BJ; Strickland LN; Li L; Vucic E; Warner AN; Pruski M; Clark T; Van Buren G; Thosani NC; Bynon JS; Wray CJ; Bar-Sagi D; Poulsen KL; Vornik LA; Savage MI; Sei S; Mohammed A; Zhao Z; Brown PH; Mills T; Eltzschig HK; McAllister F; Bailey-Lundberg JM
Cancer Res; 2023 Apr; 83(7):1111-1127. PubMed ID: 36720042
[TBL] [Abstract][Full Text] [Related]
16. C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer.
Sasaki K; Takano S; Tomizawa S; Miyahara Y; Furukawa K; Takayashiki T; Kuboki S; Takada M; Ohtsuka M
J Exp Clin Cancer Res; 2021 Jun; 40(1):212. PubMed ID: 34167573
[TBL] [Abstract][Full Text] [Related]
17. SUMOylation inhibitors activate anti-tumor immunity by reshaping the immune microenvironment in a preclinical model of hepatocellular carcinoma.
Wang Z; Pan B; Su L; Yu H; Wu X; Yao Y; Zhang X; Qiu J; Tang N
Cell Oncol (Dordr); 2024 Apr; 47(2):513-532. PubMed ID: 38055116
[TBL] [Abstract][Full Text] [Related]
18. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma.
Ene-Obong A; Clear AJ; Watt J; Wang J; Fatah R; Riches JC; Marshall JF; Chin-Aleong J; Chelala C; Gribben JG; Ramsay AG; Kocher HM
Gastroenterology; 2013 Nov; 145(5):1121-32. PubMed ID: 23891972
[TBL] [Abstract][Full Text] [Related]
19. SUMOylation inhibitor TAK-981 (subasumstat) synergizes with 5-azacytidine in preclinical models of acute myeloid leukemia.
Gabellier L; De Toledo M; Chakraborty M; Akl D; Hallal R; Aqrouq M; Buonocore G; Recasens-Zorzo C; Cartron G; Delort A; Piechaczyk M; Tempé D; Bossis G
Haematologica; 2024 Jan; 109(1):98-114. PubMed ID: 37608777
[TBL] [Abstract][Full Text] [Related]
20. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
